Abdominal Pain News and Research

RSS

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Onconova Therapeutics, Inc. announced two advances in the clinical development of ESTYBON (rigosertib, ON 01910.Na) in presentations at the annual meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011, in Chicago, Illinois.

6 Jun 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech, a member of the Roche Group, today announced results from OCEANS, a Phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

6 Jun 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Incyte Corporation announced today results from the global, pivotal Phase III clinical program of ruxolitinib in patients with myelofibrosis (MF) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.

6 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

Screening unhelpful in lowering deaths from ovarian cancer

New research shows that women regularly screened for ovarian cancer are just as likely to die from the disease. This comes as no surprise as there are still no adequate detection methods, says Ovarian Cancer Australia. Of the 1,200 Australian women diagnosed with ovarian cancer each year, 800 die, often because it is diagnosed too late to be treated.

5 Jun 2011

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Bristol-Myers Squibb Company announced today it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.

4 Jun 2011

Canadian women more aware of ovarian cancer now, but misconceptions remain

Canadian women know more about ovarian cancer than they did six years ago, but misconceptions remain that could lead to late diagnosis of the country's most fatal gynecologic cancer - a disease that claims the lives of 70% of those diagnosed.

30 May 2011

Optimer receives FDA approval for Dificid tablets to treat C. difficile-associated diarrhea

The U.S. Food and Drug Administration today approved Dificid tablets for the treatment of Clostridium difficile-associated diarrhea.

30 May 2011

WGO to focus on diarrheal disease prevention, management during World Digestive Health Day

Diarrheal disease, a common gastrointestinal problem with potentially fatal implications in the developing world is the focus of World Digestive Health Day on May 29. Infections that cause diarrhea are serious public health challenges, both in the United States and globally.

27 May 2011

Mayoly-Spindler, ProteaBio complete MS1819 Phase I/IIA trial in malabsorption syndrome

ProteaBio Europe SAS, announced today that the company, in partnership with Mayoly-Spindler, has successfully completed a Phase I/IIA human clinical trial for their MS1819 recombinant Lipase.

26 May 2011

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).

23 May 2011

FDA approves SUTENT for treatment of pancreatic NET

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.

21 May 2011

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

Salix Pharmaceuticals, Ltd. today announced findings from two analyses of a Phase 3 open-label study of RELISTOR (methylnaltrexone bromide) presented at the 30th Annual Scientific Meeting of the American Pain Society. The meeting is being held in Austin, TX, on May 19-21, 2011.

21 May 2011

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

The U.S. Food and Drug Administration today approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body (metastatic).

21 May 2011

Monitoring adherence to mandatory hand-washing protocols can help stop outbreaks of C. diff bacteria

Just like intelligence agents watching for the real terrorists threatening to attack, monitoring healthcare worker adherence to mandatory hand-washing protocols via hand-washing squads in hospitals can go a long way to stop outbreaks of the opportunistic C. diff bacteria, says Irena Kenneley, an infection prevention and control expert and assistant professor of nursing from the Frances Payne Bolton School of Nursing at Case Western Reserve University.

20 May 2011

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

The U.S. Food and Drug Administration today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of the ACCORD Lipid study as they relate to the use of fenofibric acid (sold as Trilipix in the United States) in combination with a statin in patients with mixed dyslipidemia and at high risk of heart disease.

20 May 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free survival and time-to-progression.

20 May 2011

Naltrexone improves clinical, inflammatory activity in Crohn's disease patients

Naltrexone reduced inflammation in Crohn's patients in a research study at Penn State College of Medicine.

20 May 2011

$Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma$

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.

20 May 2011

Abdominal Pain News and Research

Further Reading

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Screening unhelpful in lowering deaths from ovarian cancer

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Canadian women more aware of ovarian cancer now, but misconceptions remain

Optimer receives FDA approval for Dificid tablets to treat C. difficile-associated diarrhea

WGO to focus on diarrheal disease prevention, management during World Digestive Health Day

Mayoly-Spindler, ProteaBio complete MS1819 Phase I/IIA trial in malabsorption syndrome

Vertex receives FDA approval for INCIVEK to treat hepatitis C

FDA approves SUTENT for treatment of pancreatic NET

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

Monitoring adherence to mandatory hand-washing protocols can help stop outbreaks of C. diff bacteria

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Naltrexone improves clinical, inflammatory activity in Crohn's disease patients

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News